Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiechangyan Shuan is a Traditional Chinese Medicine (TCM) suppository developed for the treatment of ulcerative colitis and chronic proctitis. It is a multi-herbal formulation containing extracts from Sophorae Flavescentis Radix, Sanguisorbae Radix, Galla Chinensis, Indigo Naturalis, Bletillae Rhizoma, and Corydalis Rhizoma. The medication is designed for rectal administration, allowing for high local concentrations of active constituents at the site of colonic inflammation. Its primary mechanism of action involves the inhibition of pro-inflammatory cytokines (such as TNF-α and IL-6) and the modulation of the NF-κB signaling pathway, which reduces mucosal inflammation and promotes the healing of intestinal ulcers. Jinan Kangzhong Pharmaceutical Technology Development Co., Ltd. is a key developer of this formulation, which is widely manufactured and marketed in China for gastrointestinal disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jiechangyan shuan.